Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A crystal of lipocalin-type prostaglandin D synthase derived from mouse.

2. (original) A crystal as claimed in Claim 1 which has orthorhombic system space group $P2_12_12_1$ and in which the size of unit cell is a=46.2±0.5 Å, b=66.8±0.7 Å, and c=105.3±1.0Å.

3. (original) A crystal as claimed in Claim 1 which has orthorhombic system space group $C222_1$ and in which the size of unit cell is a=45.7±0.5 Å, b=66.8±0.7 Å, and c=104.5±1.0 Å.

4. (original) Lipocalin-type prostaglandin D synthase having a three dimensional structure represented by the structural coordinates in Table 2.

5. (original) Lipocalin-type prostaglandin D synthase having a three dimensional structure represented by the structural coordinates in Table 3.

6. (original) Use of the structural coordinates in Table 2 or 3 for the selection of a compound which inhibits lipocalin-type prostaglandin D synthase.

7. (original) A method for selecting an inhibitor of lipocalin-type prostaglandin D synthase, which comprising

(a) providing the three dimensional structure coordinates in Table 2 or 3 representing three dimensional structure of lipocalin-type prostaglandin D synthase;

(b) providing three dimensional structures of candidate compounds; and

(c) selecting the candidate compound which fits to the substrate-binding site of lipocalin-type prostaglandin D synthase as inhibitor.

8. (original) A method as claimed in Claim 7, further comprising

(d) contacting the inhibitor as selected above with lipocalin-type prostaglandin D synthase in the presence of prostaglandin

H_2 to measure L-PGDS enzyme activity to confirm the inhibiting effect of the inhibitor selected.

9. (currently amended) An inhibitor for lipocalin-type prostaglandin D synthase selected by the method of Claim 7~~ or 8~~.

10. (original) An inhibitor for lipocalin-type prostaglandin D synthase which is 4-dibenzo(a,d)cyclohepten-5-ylidene-1-(4-(2H-tetrazole-5-yl)butyl)piperidine.

11. (new) An inhibitor for lipocalin-type prostaglandin D synthase selected by the method of Claim 8.